New York, NY, Dec. 29, 2015 (GLOBE NEWSWIRE) -- Intrommune Therapeutics (“Intrommune”), a New York City-based biotechnology company developing patient-friendly therapies for food allergy, today announced that it will be scheduling meetings around the JP Morgan 34th Annual Healthcare Conference on January 11-14, 2016 in San Francisco, CA. Chief Executive Officer Michael Nelson, JD, and Chief Operating Officer Erick Berglund, PhD, will be providing corporate updates.
Intrommune’s lead product is INT-301 for the treatment of peanut allergy. INT-301 leverages the novel oral mucosal immunotherapy (OMIT) platform to integrate peanut allergy desensitization therapy into a patient’s everyday tooth brushing routine. Intrommune has exclusive global rights to develop OMIT for food allergy. There is currently no FDA-approved treatment for food allergy, including peanut allergy.
CEO Michael Nelson stated, “There is significant interest from the research, patient, and business communities in finding a safe, effective, and durable treatment for life-threatening food allergy, including peanut allergy. Our intuitive approach is backed by sound science and leading researchers. We are in a position to truly improve the lives of people with this serious condition.”
Intrommune is in talks with key food allergy thought leaders in the field of allergy and immunology. COO Erick Berglund said, “We are encouraged by the enthusiastic response of the scientific community. Our approach promises to improve patient outcomes, side effects profile, and adherence to therapy over the alternatives under studied by competitors and in academic research settings.”
Company executives will be available for meetings in the Bay Area during the JP Morgan Healthcare Conference. For more information or to set up a meeting, please contact Jennifer K. Zimmons, Ph.D. at (917) 214-3514 or email@example.com.
Source: Intrommune Therapeutics